{"title":"Molecular Docking Studies of Deva Chooranam against the Target Protein 6LU7 of Novel Corona Virus 2019","authors":"K. Thangadurai, Rengasundari, P SaravanaSiva, N Vithyavani, K. Sivasankari, R. Ramya, R JeevaGladys, K. Kannan","doi":"10.35652/IGJPS.2020.10204","DOIUrl":null,"url":null,"abstract":"Plants and bioactive compounds have played an important role in the development of several clinically useful therapeutic agents since time immemorial. In the recent years, more emphasis has been placed on identifying plant-derived compounds that can be used as an effective treatment for life-threatening diseases. COVID-19, a new strain of coronavirus (CoV), was identified in Wuhan, China, in 2019. No specific therapies are available and investigations regarding COVID-19 treatment are lacking. Bioactive compounds found in Siddha herbal formulation Deva Chooranam which was previously confirmed through molecular docking to have antiviral effects against HIV -RT. The present study aimed to assess Deva Chooranam as potential COVID-19 Mpro inhibitor. Molecular docking was performed using Autodock 4.2, with the Lamarckian Genetic Algorithm and results were visualized using pymol. The physiochemical and ADMET(Adsorption, distribution, metabolism and excretion) properties were also analysed.COVID-19 Mpro was docked with several compounds, Eugenol A-Pinene, Atlantone, Myrcene, Luteolin, Apigenin, Kaempferol and docking was analysed using Pymol. The results showed that out of the 7 compounds screened Luteolin appeared to have the best potential binding against the COVID-19 Mpro 6LU7. However, further research is necessary to investigate their potential medicinal use. © 2020 iGlobal Research and Publishing Foundation. All rights reserved.","PeriodicalId":13366,"journal":{"name":"Indo Global Journal of Pharmaceutical Sciences","volume":"29 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Indo Global Journal of Pharmaceutical Sciences","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.35652/IGJPS.2020.10204","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1
Deva Chooranam抗新型冠状病毒靶蛋白6LU7的分子对接研究
自古以来,植物和生物活性化合物在一些临床有用的治疗剂的开发中发挥了重要作用。近年来,人们越来越重视鉴定植物源性化合物,以有效治疗危及生命的疾病。2019年,在中国武汉发现了一种新型冠状病毒COVID-19。没有特定的治疗方法,也缺乏关于COVID-19治疗的调查。在Siddha草药制剂Deva Chooranam中发现的生物活性化合物,先前通过分子对接证实对HIV -RT具有抗病毒作用。本研究旨在评估Deva Chooranam作为潜在的COVID-19 Mpro抑制剂。使用Autodock 4.2进行分子对接,使用lamarkian遗传算法,并使用pymol将结果可视化。分析了其理化性质和ADMET(吸附、分布、代谢和排泄)特性。COVID-19 Mpro与丁香酚a -蒎烯、亚特兰大酮、月桂烯、木犀草素、芹菜素、山奈酚等化合物对接,并使用Pymol分析对接情况。结果表明,在筛选的7个化合物中,木犀草素对COVID-19 Mpro 6LU7的结合潜力最好。然而,有必要进一步研究其潜在的药用价值。©2020全球研究与出版基金会。版权所有。
本文章由计算机程序翻译,如有差异,请以英文原文为准。